Trial Profile

An Open Label, Randomized, Multicenter study to Evaluate and Compare the Immunogenicity and Reactogenicity of DTwP-Hib-IPV vaccine (EasyfourPolTM, Panacea Biotec Ltd.) with QuadrovaxTM (Tetravalent DTwP/Hib Vaccine, Serum Institute of India Ltd.) Co Administered with Imovax PolioÂ® (Salk Based Inactivated Polio Vaccine, Sanofi Pasteur India Pvt. Ltd.) in Healthy Infants. - Easyfour Pol Study

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 03 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hib-DTP-poliovirus vaccine (Primary)
Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics
Sponsors Panacea Biotec

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com